Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 7, 2025Bleeding Thrombosis and Vascular BiologyOpen Access

PO43 | Extended treatment with reduced dose of direct oral anticoagulants in patients with venous thromboembolism: a retrospective study

View Full Paper
Ask AI
Bookmark
Share

Discussion

Loading...

Member takes

Overview

Retrospective study finds low recurrent VTE and major bleeding rates in patients treated with reduced-dose DOACs, suggesting a need for individualized risk assessment.

Key Points

  • The study assessed 140 patients treated with reduced doses of direct oral anticoagulants for VTE.
  • Recurrent VTE incidence was low at 0.7%, and major bleedings occurred in 2.9% of patients.
  • Most patients received apixaban (73.6%) and few experienced relevant bleeding complications.
  • Higher arterial thrombotic events compared to recurrent VTE indicate careful consideration of treatment risks.

Cite This Study

A 2025 study studied this question.

synapsesocial.com/papers/689521e49f4f1c896c427fbahttps://doi.org/10.4081/btvb.2025.306
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Three Year Follow-Up of Reduced Dose of Direct Oral Anticoagulants for Extended Treatment of Venous Thromboembolism: An Ambispective Cohort Study.2025 · 1 citations
  2. 2Reduced Versus Full-Dose Direct Oral Anticoagulants for Long-Term Management of Venous Thromboembolism: A Systematic Review2026 · 2 citations
  3. 3Long-Term Efficacy and Safety of Direct Oral Anticoagulants at Reduced Doses in the Secondary Prevention of Venous Thromboembolism and Post-Thrombotic Syndrome2024 · 2 citations
  4. 4Efficacy and safety of low-dose vs. standard-dose direct oral anticoagulants for secondary prevention of venous thromboembolism: A systematic review and meta-analysis2025
  5. 5Clinical characteristics, prescription patterns and clinical outcomes of patients with extended therapy with direct oral anticoagulants for unprovoked venous thromboembolism2026